Hong Kong has formally become a regulatory member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), a move the Health Bureau says marks a key step towards building the city into an international healthcare innovation hub. The ICH admitted Hong Kong, represented by the Pharmacy and Poisons Board, as its 20th regulatory member at its assembly in the Czech Republic on Tuesday. Other regulatory members include the National Medical Products Administration of China, as well as regulators from Europe, Switzerland, the UK and the US. The ICH is a key international platform for coordinating technical standards on drug regulation, setting guidelines covering safety, efficacy and quality. Secretary for Health Lo Chung-mau said the government sincerely thanked the country for its support for Hong Kong's development as an international healthcare innovation hub, saying the membership fully demonstrates the unique advantages of "one country, two systems". He noted that Hong Kong became an ICH observer on October 31, 2023, and had met all of the body's requirements in just three years, far faster than the eight to 10 years estimated earlier. Lo said the government will set up a centre for medical products regulation to build independent drug evaluation and approval...
Read full article